Hemagen Diagnostics (Hemagen Diagnostics) Total Stockholders Equity : $-3.56 Mil (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Total Stockholders Equity?

Hemagen Diagnostics's Total Stockholders Equity for the quarter that ended in Sep. 2012 was $-3.56 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Hemagen Diagnostics's Book Value per Share for the quarter that ended in Sep. 2012 was $-0.23. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Hemagen Diagnostics's Debt-to-Equity for the quarter that ended in Sep. 2012 was -1.41.

Hemagen Diagnostics Total Stockholders Equity Historical Data

The historical data trend for Hemagen Diagnostics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Total Stockholders Equity Chart

Hemagen Diagnostics Annual Data

Trend

Sep03

Sep04

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Total Stockholders Equity

Get a 7-Day Free Trial

-1.10

-1.78

-1.85

-2.69

-3.56

Hemagen Diagnostics Quarterly Data
	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12
Total Stockholders Equity	Get a 7-Day Free Trial															-2.69	-3.04	-3.25	-3.43	-3.56

Hemagen Diagnostics (OTCPK:HMGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Hemagen Diagnostics's Book Value per Share for the quarter that ended in Sep. 2012 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-3.557	-	0)	/	15.6003
	=	-0.23

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Hemagen Diagnostics's Debt-to-Equity for the quarter that ended in Sep. 2012 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.977	+	4.05)	/	-3.557
	=	-1.41

Hemagen Diagnostics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

9033 Red Branch Road, Columbia, MD, USA, 21045

Website

http://www.hemagen.com

Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.

Executives

Howard F Curd

director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines